Study reveals an association between intestinal inflammation and the gut microbiome in the development and progression of ALS.
A new treatment for ALS, which uses a technique that turns off the mutated SOD1 gene, has passed an early phase clinical trial for safety.
Researchers demonstrate it is possible to modify gene expression in upper motor neurons.
Research using C. elegans finds maple syrup may protect neurons and prevent the development of ALS.
Mislocalization of the TDP-43 protein alters the genetic instructions for UNC13A. The findings provide a potential new therapeutic target for the treatment of ALS and frontotemporal dementia.
The TBK1 gene regulates the disease progression of ALS in mouse models of the neurodegenerative disease. Loss of the TBK1 gene in motor neurons increases SOD1 aggregation and accelerates the onset of the disease.
PolyP, an inorganic polyphosphate released by astrocytes in people with ALS and frontotemporal dementia contributes to the signature motor neuron death associated with the disease pathologies.
Changes in gene expression help researchers identify ALS associated pathways and establish the key drivers of motor neuron degeneration in the disease.
Using a tiny dose of the leukemia drug nilotinib, researchers halt the accumulation of toxic proteins linked to Parkinson's diseases in the brains of mice.
Microglia plays crucial roles both in healthy and diseased brains, a new study reports.
New research could help find a solution to slowing down the progression of motor neuron disease.
Researchers have identified the gene STMN2 as a novel biomarker and potential drug target for ALS.
